ABSTRACT
Traditional disease-modifying antirheumatic drugs (DMARDs) are prescribed as a first line of therapy in psoriatic arthritis (PsA), especially in patients with the peripheral arthritis domain. Although different reviews and meta-analyses have been demonstrated, there has been little high-quality evidence supporting the efficacy of these drugs in PsA, due to the small number of studies. Thus, dissimilar outcomes are evaluated and there are high withdrawal rates [3–7]. In this chapter, we review the literature on different DMARDs.
